From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Emerging H7N9 Influenza Demonstrates Antiviral Drug Resistance

by Global Biodefense Staff
May 29, 2013

Emergence of Avian Influenza A(H7N9)Drug resistance to the primary influenza treatment Tamiflu appears to develop easily with the new H7N9 avian flu, according to a new study recently published in The Lancet.

H7N9 has already demonstrated resistance to the only other class of flu treatments available, known as adamantane drugs, leaving few tools to fight the infections should the virus become more easily transmissible among people.

The study authors found that in 14 H7N9 patient specimens in China, two developed resistance to Tamiflu. Doctors in Taiwan treating a patient that had recently traveled to China identified a third such resistant mutation.

“The apparent ease with which antiviral resistance emerges in (H7N9) viruses is concerning,” said the study authors. “It needs to be closely monitored and considered in future pandemic response plans.”

The study demonstrated treatment with Tamiflu, even administered 48 hours or more after disease onset, reduced the viral load in the majority of patients and is still a recommended treatment course for H7N9 cases.

Read the study at The Lancet: Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance (.pdf)

From Our Partners
Tags: AntiviralsAvian InfluenzaEmerging ThreatsH7N9InfluenzaPandemic

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC